141 related articles for article (PubMed ID: 20007626)
1. New opportunities for the management and therapy of hepatitis C in correctional settings.
Martin CK; Hostetter JE; Hagan JJ
Am J Public Health; 2010 Jan; 100(1):13-7. PubMed ID: 20007626
[TBL] [Abstract][Full Text] [Related]
2. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.
Nguyen JT; Rich JD; Brockmann BW; Vohr F; Spaulding A; Montague BT
J Urban Health; 2015 Aug; 92(4):635-49. PubMed ID: 25828149
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
[TBL] [Abstract][Full Text] [Related]
4. FDA approves new combination treatment for hepatitis C. Food and Drug Administration.
Baker R
BETA; 1998 Jul; ():10. PubMed ID: 11365553
[TBL] [Abstract][Full Text] [Related]
5. Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
Mangin EF; Jones WN
Am J Health Syst Pharm; 2004 Jul; 61(14):1479-82. PubMed ID: 15332696
[No Abstract] [Full Text] [Related]
6. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
7. ANTIVIRAL TREATMENT OF HEPATITIS C IN SERBIAN PRISON SETTING: MEDICAL TREATMENT OUTCOMES AND PATIENTS' ADHERENCE.
Simonović Babić J; Bojović K; Delić D; Katanić N; Mitrović N; Malinić J
Med Pregl; 2016; 69(3-4):85-91. PubMed ID: 27506095
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
9. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy for hepatitis C infection.
Newman TB
N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206843
[No Abstract] [Full Text] [Related]
11. Management of hepatitis C in Rhode Island: opportunities for improvement within and beyond the department of corrections.
Berzin T; Allen S; Taylor L; Rich J; Feller E
Med Health R I; 2002 Nov; 85(11):341-4. PubMed ID: 12462866
[No Abstract] [Full Text] [Related]
12. Treating hepatitis C in the prison population is cost-saving.
Tan JA; Joseph TA; Saab S
Hepatology; 2008 Nov; 48(5):1387-95. PubMed ID: 18924228
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness evaluation of hepatitis C therapy in Lahore.
David YJ; Tahir A; Riaz M
Pak J Pharm Sci; 2017 Nov; 30(6):2233-2237. PubMed ID: 29175794
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin.
Yu ML; Hou NJ; Dai CY; Chang WY; Chuang WL
Antimicrob Agents Chemother; 2005 Sep; 49(9):3986-7. PubMed ID: 16127091
[No Abstract] [Full Text] [Related]
16. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy.
Balan V; Rosati MJ; Anderson MH; Rakela J
Dig Dis Sci; 2006 May; 51(5):956-9. PubMed ID: 16758306
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C: The role of new interferons in the era of STAT-C.
Moucari R; Marcellin P
Nat Rev Gastroenterol Hepatol; 2009 Sep; 6(9):509-11. PubMed ID: 19713984
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
